From January 1, 2027, Novo Nordisk has announced a list-price reduction to approximately $675 per month
Hence, betaine therapy may be beneficial not only in liver disease but also in other health conditions which are linked with inflammation, such as obesity, heart diseases, and Alzheimers disease (Mathieu et al., 2010
width: 1050 m) designed to penetrate the stratum corneum barrier and create transient microchannels for painless, transdermal drug administration into the dermis (Kumar and Shukla, 2024)
The 2.5 mg dose is used only for initiation and is not intended for glycemic control
Nutritional Guidance: Registered dietitians provide expert advice on balanced and nutritious diets that support your weight loss journey
The recommended monitoring panel includes: Baseline and Ongoing Laboratory Tests: Comprehensive Metabolic Panel (CMP): Monitors kidney function, liver enzymes, and electrolytes Hemoglobin A1c or Fasting Glucose: Assesses glycemic control Lipid Panel: Evaluates cardiovascular risk markers Thyroid Function Tests (TSH, Free T3, Free T4): Screens for thyroid dysfunction Complete Blood Count (CBC): Monitors for hematologic changes Vitamin B12 and Vitamin D: Assesses nutritional status Monitoring Schedule: Baseline testing before initiation Follow-up at 3, 6, and 12 months during active treatment Annual monitoring for stable patients on maintenance therapy Nutritional Supplementation Protocol Given the appetite-suppressing effects of GLP-1 agonists and the increased nutritional needs of perimenopausal women, targeted supplementation is recommended: Essential Supplements: Vitamin D3 (2000-5000 IU daily): For bone health and metabolic support Magnesium Glycinate (200-400 mg at bedtime): For muscle function and sleep quality High-quality multivitamin with iron: To prevent micronutrient deficiencies Omega-3 fatty acids (1000-2000 mg daily): For cardiovascular and anti-inflammatory support Protein supplementation: To meet increased protein needs (1.2-1.6 g/kg body weight daily) Calcium with Vitamin K2: For bone health, particularly important during menopause Clinical Implementation and Patient Selection Ideal Candidates for Microdosing GLP-1 Therapy: Perimenopausal women with BMI 25 experiencing hormonal weight gain Patients with documented appetite dysregulation or carbohydrate cravings Women with early metabolic syndrome markers (elevated waist circumference, insulin resistance) Those seeking prevention of further weight gain during hormonal transitions.[3] Contraindications: Personal or family history of medullary thyroid carcinoma or MEN2 syndrome History of pancreatitis or severe gastrointestinal disorders Severe renal or hepatic impairment Pregnancy or planned pregnancy Expected Outcomes and Timeline Clinical studies demonstrate that perimenopausal women can expect 5-15% body weight reduction over 6-12 months with GLP-1 therapy
